Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue 12, 2000, Pages 1386-1392

  Brown, Wendy A ^a   Skinner, Stewart A ^a   Malcontenti Wilson, Caterina ^a   Misajon, Aileen ^a   Dejong, Tanya ^a   Vogiagis, Daphne ^a   O'Brien, Paul E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Aberrant crypts; Chemoprevention; Colorectal cancer; Gastrotoxicity; Non steroidal anti inflammatory drugs

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; SULINDAC SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; CRYPT CELL; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL MODEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH LAVAGE; TOXICITY;

EID: 0034525501     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02370.x     Document Type: Article

References (48)

1. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat
2. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis
3. Sulindac and indomethacin inhibit formation of aberant crypt loci in the colons of dimethyl hydrazine treated rats
4. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent
5. Colorectal cancer risk, chronic illnesses, operations and medications: Case control results from the Melbourne colorectal cancer study
6. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
7. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
8. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs
9. Towards a better aspirin
10. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
11. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: Possible physiological and therapeutic implications
12. Cyclooxygenase-2 inhibitors - A new class of anti-inflammatory agents that spare the gastrointestinal tract
13. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
14. A gut check for PPARγ
15. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg; piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers
16. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
17. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumours
18. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
19. Suppression of intestinal polyposis in APC-716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
20. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide a selective inhibitor of cyclooxygenase 2
21. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats
22. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
23. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
24. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen - Preliminary findings
25. Aberrant crypts: Putative preneoplastic foci in human colonic mucosa
26. Sequential analysis of the growth and morphological characteristics of aberrant crypt foci: Putative preneoplastic lesions
27. Aberrant crypts as a biomarker for colon cancer: Evaluation of potential chemopreventive agents in the rat
28. Pathogenesis and biological behaviour of 1,2-dimethylhydrazine-induced colonic neoplasms in the mouse
29. Expression of ras oncogene mRNA and protein in aberrant crypt foci
30. Apc mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in rats
31. An evaluation of the phenomenon of cytoprotection using quantitative histological criteria
32. Sequence of gastric mucosal injury following ischemia and reperfusion
33. COX-2 inhibitors - A new generation of safer NSAIDs?
34. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
35. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
36. Repair of rat gastric mucosa: Effect of 16,16-dimethyl prostaglandin E2
37. Gastric mucosal damage induced by nonsalicylate nonsteroidal antiinflammatory drugs in rats is mediated systemically
38. Eicosanoids in neoplasia
39. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats
40. Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat
41. Sulindac causes rapid regression of pre-existing tumours in Min/+ mice independent of prostaglandin biosynthesis
42. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
43. Mechanisms underlying nonsteroidal antiinflammatory drug mediated apoptosis
44. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance
45. Nonsteroidal anti-inflammatory drug gastropathy - Is it preventable?
46. The effect of sulindac and its metabolites on acute stress-induced gastric ulcers in rats
47. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase
48. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells